* Industry diversification based on Moody's industry classification. Measured as the fair value of investments for each category against the total fair value of all investments. Totals may not sum due to rounding.

A balanced portfolio built on the cornerstones of diversification and selectivity
Anchored in senior secured loans, NCDL has built a scaled and diversified portfolio by industry, investment type and portfolio company. Selectivity, diversification and rigorous underwriting are key to our investment philosophy, enabling strong credit performance since inception.
Portfolio holdings
Top ten positions
Represents the top ten positions in NCDL based on Fair Value as of June 30, 2025
Company | Fair value ($ in thousands) | Industry | Asset Types | Pricing1 |
---|---|---|---|---|
Solve Industrial Motion Group LLC | 1,806,430 | High Tech Industries | Subordinated Debt | 10.00% (Cash) 2.00% (PIK) |
Solve Industrial Motion Group LLC | 788,173 | High Tech Industries | Subordinated Debt | 10.00% (Cash) 2.50% (PIK) |
Alta Buyer, LLC (GoEngineer) | 5,310,931 | High Tech Industries | First Lien Debt | S + 5.00% |
VALIDITY INC | 99,000 | High Tech Industries | First Lien Debt | S + 5.25% |
North Haven CS Acquisition, Inc. | 5,681,667 | High Tech Industries | First Lien Debt | S + 5.25% |
Alta Buyer, LLC (GoEngineer) | 3,103,723 | High Tech Industries | First Lien Debt (Delayed Draw) | S + 5.00% |
Prosci, Inc. | 4,733,333 | High Tech Industries | First Lien Debt | S + 4.25% |
Impact Advisors, LLC | (69,595) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 4.75% |
Wellspring Pharmaceutical Corporation | 2,551,118 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.00% |
Healthspan Buyer, LLC (Thorne HealthTech) | 10,337,055 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
Impact Advisors, LLC | 12,700,041 | Healthcare & Pharmaceuticals | First Lien Debt | S + 4.75% |
JKC Buyer, Inc. (J. Knipper and Company Inc) | 2,090,896 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.00% |
GHR Healthcare, LLC | (96,451) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
GHR Healthcare, LLC | (32,136) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
JKC Buyer, Inc. (J. Knipper and Company Inc) | 6,040,365 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.00% |
GHR Healthcare, LLC | 4,664,127 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
Infucare Rx Inc | 2,712,408 | Healthcare & Pharmaceuticals | First Lien Debt | S + 4.25% |
Wellspring Pharmaceutical Corporation | 1,228,774 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.00% |
Genesee Scientific LLC | 5,199,304 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.75% |
Heartland Veterinary Partners LLC | 10,279,562 | Healthcare & Pharmaceuticals | Subordinated Debt (Delayed Draw) | 7.50% (Cash) 7.00% (PIK) |
Bridges Consumer Healthcare Intermediate LLC | 2,142,954 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
GHR Healthcare, LLC | 5,991,022 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
Heartland Veterinary Partners LLC | 2,055,912 | Healthcare & Pharmaceuticals | Subordinated Debt | 7.50% (Cash) 7.00% (PIK) |
Coding Solutions Acquisition, Inc. | (5,950) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.00% |
GHR Healthcare, LLC | 7,610,657 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
Bridges Consumer Healthcare Intermediate LLC | 5,660,139 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
HemaSource, Inc. | 5,227,207 | Healthcare & Pharmaceuticals | Subordinated Debt | 13.50% |
Coding Solutions Acquisition, Inc. | 12,611,517 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.00% |
HMN Acquirer Corp. | 6,462,873 | Healthcare & Pharmaceuticals | First Lien Debt | S + 4.50% |
Health Management Associates, Inc. | 8,207,072 | Healthcare & Pharmaceuticals | First Lien Debt | S + 6.25% |
1. The majority of the investments bear interest at rates that may be determined by reference to Secured Overnight Financing Rate ("SOFR" or "S"), which reset monthly or quarterly. For each such investment, the Company has provided the spread over SOFR and the current contractual interest rate in effect at June 30, 2025. As of June 30, 2025, rates for 1M S, 3M S, 6M S, 12M S ("SOFR") are 4.32%, 4.29%, 4.15%, and 3.88% respectively. Certain investments are subject to a SOFR floor or may utilize an alternative reference rate such as U.S. Prime Rate (“P”). For fixed rate loans, a spread above a reference rate is not applicable.